Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women

What Was Tested

The paper reports a study of Angiotensin II, published as a randomized controlled trial.

The aim of this study was to compare the effects of trandolapril and losartan on plasminogen activator inhibitor type 1 (PAI-1) levels and insulin sensitivity in hypertensive postmenopausal women.

At the end of the placebo and active treatment periods, blood pressure (BP) was measured, plasma samples were drawn to evaluate PAI-1 antigen levels, and insulin sensitivity was assessed.

Why It Was Studied

Diabetic, obese, and smoking patients were excluded.

Who Took Part

PubMed indexes the participants as middle-aged adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

The Angiotensin II group and the comparison group ran side by side rather than switching.

The methods mention a period of 4 weeks.

What Was Measured

PubMed files the paper under topics including Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Glucose, Blood Pressure, Fibrinolysis and Hypertension.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II over 4 weeks.

The publication is from 2001 (American journal of hypertension), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.